Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-386.85K) by net assets ($-9.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Liminatus Pharma, Inc. Class A Common St fund operations to measure how many days the company can operate on defensive assets alone.
Liminatus Pharma, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pulmatrix Inc
NASDAQ:PULM
|
-0.218x |
|
Philly Shipyard ASA
OL:PHLY
|
-4.976x |
|
Siamraj Public Company Limited
BK:SR
|
0.026x |
|
Alefarm Brewing AS
CO:ALEFRM
|
0.098x |
|
Enova Mining Ltd
AU:ENV
|
-0.031x |
|
Compodium International AB
ST:COMPDM
|
0.043x |
|
Narryer Metals Ltd
AU:NYM
|
-0.261x |
|
First Venture Sweden AB Series B
ST:FIRST-B
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Liminatus Pharma, Inc. Class A Common St.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-9.81 Million | $-9.96 Million | 1.015x | +418.60% |
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -37.43% |
| 2023-12-31 | $-10.69 Million | $-3.35 Million | 0.313x | +146.59% |
| 2022-12-31 | $1.29 Million | $-869.00K | -0.671x | -13974.82% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.